-
Mashup Score: 3Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? - 6 day(s) ago
In the past 15 years, treatment frameworks for newly diagnosed multiple myeloma have radically changed. It is important to recall that as recently as 2010, Rajkumar and colleagues1 presented ECOG E4A03, which was a phase 3 trial examining the role of lenalidomide, combined with two different dosing regimens for dexamethasone, that showed a 68% overall response rate (ORR; 10% complete remission rate) after four cycles of therapy, a result considered to be astounding at the time. Fast forward to 2024, the use of triplet induction has nearly been supplanted by four component regimens, typically including an immunomodulatory drug, a proteasome inhibitor, a steroid, and the newest addition, an anti-CD38 antibody.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Immune engager therapies, if available, should be considered as a first treatment choice following idecabtagene vicleucel treatment in multiple myeloma, according to Murali Janakiram, MD, MS.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Immune engager therapies, if available, should be considered as a first treatment choice following idecabtagene vicleucel treatment in multiple myeloma, according to Murali Janakiram, MD, MS.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM - 5 month(s) ago
Original Article from The New England Journal of Medicine — Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM - 5 month(s) ago
Original Article from The New England Journal of Medicine — Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10BCMA-CAR T-cell treatment–associated parkinsonism - 7 month(s) ago
In this issue of Blood, Graham et al1 and Karschnia et al2 provide new insights into the rare hypokinetic movement disorder (also termed movement and neurocogni
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4GC012F CAR T Shows 100% Complete Response Rate in Multiple Myeloma - 8 month(s) ago
Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma treatment at the International Myeloma Society Annual Meeting.
Source: www.targetedonc.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Blood Cancer Journal – Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
The FDA has accepted a supplemental biologics license application seeking the approval of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
RT @GvHD_Meade: Autologous transplant has been in the ICU for a while... https://t.co/YdAOvEt7z1